Andrew Lerner, Ph.D.

Patent Lead
andrew@rockridgelaw.com

• National Institutes of Health (NIH) RADx Faculty Member
• B.S., UC Berkeley; Ph.D., UNC Chapel Hill
• Veteran U.S.M.C., Russian cryptologist

Background

Andrew Lerner, Ph.D. is the Patent Lead at Rockridge Venture Law®, a Certified B Corp law group and both 2018 & 2019 Best For The World: Community honoree. Andrew is a registered patent agent and his practice areas include clearance & patentability analyses, patent prosecution, and due diligence; strategic IP portfolio development; and IP diligence for life science venture funds.

Andrew has supported faculty, researchers, and staff involved in innovation and commercialization at Duke University Innovation & Entrepreneurship and the University of North Carolina, Chapel Hill Eshelman Institute for Innovation. He has led IP activities for life science and biotechnology seed funding for early-stage technologies and ideas and has advised translational researchers across broad disciplines, including biomedical engineering, pharmacology & cancer biology, and medicine.

As an entrepreneur, Andrew Lerner has acted as a key advisor to startups developing bispecific antibody therapeutics and testing entire communities for COVID-19. Andrew has served as a reviewer for proposals for seed stage funding, and he regularly advises entrepreneurs as a mentor through Veterati, a platform that connects mentors with Service Members, Veterans, and Military Spouses.

Andrew’s academic research has focused on engineering novel proteins to study fundamental mechanisms of epigenetic regulation at UNC Chapel Hill, as well as study of protein regulatory mechanisms at the University of California, Berkeley.

Andrew holds a Ph.D. in Biochemistry & Biophysics from the University of North Carolina, Chapel Hill, and earned a Graduate Certificate in Technology Commercialization and Entrepreneurship through coursework at the UNC Kenan-Flagler Business School. He holds a B.S. in Chemistry from the University of California, Berkeley, and an A.A. in Russian from the Defense Language Institute Foreign Language Center, Monterey, CA.

A United States Marine Corps veteran, Andrew deployed overseas and held a top-secret security clearance while serving as a signals intelligence analyst with the National Security Agency.

RVL articles by Andrew:

Why, When, and How Should I File a Patent Application?

5 Interesting IP Cases in 2019 and Why They Matter for 2020

Patent Trolling in the Time of COVID-19

Presentations & Publications

  • Lerner, Andrew et al. “An optogenetic switch for the Set2 methyltransferase provides evidence for transcription-dependent and independent dynamics of H3K36 methylation.” Genome Research. 10 June 2020. Pending resubmission.
  • Meriesh, Hashem, Lerner, Andrew et al. “The histone H4 basic patch regulates SAGA-mediated H2B deubiquitination and histone acetylation.” Journal of Biological Chemistry. 8 May. 2020. Publication.
  • Lerner, Andrew et al. “Engineering improved photoswitches for the control of nucleocytoplasmic distribution.” ACS Synthetic Biology. 15 Nov. 2018. Publication.
  • Lerner, Andrew. “Elucidating dynamics of histone post-translational modifications using optogenetics.” EpiCypher 2018: Biological and Clinical Frontiers in Epigenetics. Nassau, Bahamas. 7 Nov. 2018. Poster.
  • Yumerefendi, Hayretin, Wang, Hui, Dickinson, Daniel, Lerner, Andrew et al. “Light-dependent cytoplasmic recruitment enhances the dynamic range of a nuclear import photoswitch.” ChemBioChem. 14 Feb. 2018. Publication.
  • Lerner, Andrew. “Methylation and demethylation: an optogenetic tale of histone tails.” Smaller Eukaryotes Group Meeting, NC Biotechnology Center. Durham, NC. 12 Dec. 2017. Presentation.
  • Yumerefendi, Hayretin, Lerner, Andrew et al. “Light-induced nuclear export reveals rapid dynamics of epigenetic modifications.” Nature Chemical Biology. 18 Apr. 2016. Publication.